Company / Return on Equity (ROE)
Mirum Pharmaceuticals, Inc. Return on Equity (ROE) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-7.4%
FY2025
5-year range
-65.7% / -7.4%
FY2021-FY2025
Trend
+81.0%
vs FY2024
Sector context
#57 of 190
Health Care
What the data says
Mirum Pharmaceuticals, Inc. reports negative total equity of -7.4% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-7.4% in FY2025 with a 5-year CAGR of +52.6%.
Improved from -65.7% to -7.4% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +41.4pp
- 5-Year Change
- +52.6pp
- 10-Year Change
- -
Sector benchmark
#57 of 190 in Health CareTop 30% of 190This company -7.4% Sector average -50.4%
▼
+85.3% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 81.0% year-over-year.
- Currently 43.0pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -26.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -7.4% | +81.0% |
| FY2024 | -39.0% | +40.7% |
| FY2023 | -65.7% | -34.7% |
| FY2022 | -48.8% | +18.7% |
| FY2021 | -60.0% | +0.0% |
| FY2020 | -60.0% | -48.8% |
| FY2019 | -40.3% | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026